

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**百信集團**

PASHUN GROUP

**Pa Shun Pharmaceutical International Holdings Limited**

**百信藥業國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 574)**

## **GRANT OF SHARE OPTIONS**

This announcement is made pursuant to 17.06A of the Rules (“**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”).

The board (“**Board**”) of directors (“**Directors**”, each a “**Director**”) of Pa Shun Pharmaceutical International Holdings Limited (“**Company**”) announces that on 8 July 2016, the Company has granted to certain eligible persons (“**Grantees**”), subject to acceptance by the Grantees, share options (“**Options**”) to subscribe for an aggregate of 100,000,000 ordinary shares of HK\$0.001 each in the share capital of the Company (“**Shares**”) (upon exercise in full and subject to adjustment in accordance with the share option scheme adopted by the Company by ordinary resolution of all shareholders of the Company passed on 26 May 2015 (“**Share Option Scheme**”)) under the Share Option Scheme. Details of the Options are set out below:

Date of grant	:	8 July 2016 (“ <b>Date of Grant</b> ”)
Exercise price of Options granted	:	HK\$0.60 per Share, being the highest of (i) the closing price of HK\$0.58 of the Shares on the Date of Grant; (ii) the average closing price of HK\$0.60 of the Shares for the five trading days immediately preceding the Date of Grant; and (iii) the nominal value of the Shares (namely, HK\$0.001 per Share)

Total number of Shares to be issued upon exercise in full of the Options granted : 100,000,000 Shares

Validity period of the Options : 8 July 2016 to 31 December 2019, both dates inclusive

Consideration for the grant of the Options : HK\$1.00 to be paid by each Grantee upon the acceptance of the Options granted

As at the Date of the Grant, the Company had 1,000,000,000 Shares in issue.

Among the Options granted, Options entitling the holders thereof to subscribe for an aggregate of 8,000,000 Shares were granted to Mr. Zhang Xiongfeng (“**Mr. Zhang**”), a non-executive Director.

The grant of the Options to Mr. Zhang has been approved by the independent non-executive Directors in accordance with Rule 17.04(1) of the Listing Rules.

Save as disclosed above, none of the Grantees is a Director, chief executive or substantial shareholder of the Company, or any of their respective associate(s) (as defined in the Listing Rules).

On behalf of the Board  
**Pa Shun Pharmaceutical International Holdings Limited**  
**Chen Yenfei**  
*Chairman*

Hong Kong, 8 July 2016

*As at the date of this announcement, the executive Directors are Mr. Chen Yenfei, Mr. Shen Shun and Mr. Zhou Jian; the non-executive Directors are Mr. Li Ho Tan, Mr. Masahiro Honna and Mr. Zhang Xiongfeng; and the independent non-executive Directors are Mr. Liu Liangzhong, Mr. Wong Tak Shing and Mr. Min Feng.*